Sugi Predict

Sugi Predict / Compounds / SCHEMBL1804666

SCHEMBL1804666

SCHEMBL1804666

O=C(Nc1ncc([N+](=O)[O-])s1)c1ccccc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 10/20 0.76
▸ RAB9A P51151 10/20 0.76
▸ MEN1 O00255 9/20 0.76
▸ KMT2A Q03164 9/20 0.76
▸ STAT3 P40763 7/20 0.76
▸ PKM P14618 5/20 0.76
▸ MAPT P10636 4/20 0.74
▸ NPSR1 Q6W5P4 2/20 0.74
▸ THRB P10828 1/20 0.74
▸ MAPK9 P45984 1/20 0.74
▸ HTT P42858 3/20 0.69
▸ ALDH1A1 P00352 2/20 0.69
▸ LMNA P02545 2/20 0.69
▸ SMN1; SMN2 Q16637 2/20 0.69
▸ POLB P06746 2/20 0.68
▸ NSD2 O96028 1/20 0.66
▸ ALPL P05186 1/20 0.66
▸ ALPI P09923 1/20 0.66
▸ ALPG P10696 1/20 0.66
▸ CASP7 P55210 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27135410 0.90 STAT3 (0.69) NPC1RAB9AMEN1KMT2ASTAT3
SCHEMBL30142801 0.90 STAT3 (0.69) NPC1RAB9AMEN1KMT2ASTAT3
SCHEMBL18529253 0.89 MEN1 (0.70) NPC1RAB9AMEN1KMT2ASTAT3
SCHEMBL12974167 0.87 NPC1 (0.78) NPC1RAB9AMEN1KMT2ASTAT3
SCHEMBL18529265 0.87 NPC1 (0.60) NPC1RAB9AMEN1KMT2ASTAT3
SCHEMBL2681668 0.87 NPC1 (0.68) NPC1RAB9AMEN1KMT2ASTAT3
SCHEMBL20424302 0.86 NPC1 (0.72) NPC1RAB9AMEN1KMT2ASTAT3
SCHEMBL22680776 0.86 NPC1 (1.00) NPC1RAB9AMEN1KMT2ASTAT3
SCHEMBL881749 0.86 STAT3 (0.77) NPC1RAB9AMEN1KMT2ASTAT3
SCHEMBL2681128 0.86 STAT3 (1.00) NPC1RAB9AMEN1KMT2ASTAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5935591-A Method for treatment of equine protozoal myeloencephalitis with thiazolides ROMARK LABORATORIES, L.C. (US) 1999-08-10 — — US claimed
US-20240417381-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF NITAZOXANIDE AND INTERMEDIATES THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED (IN) 2024-12-19 — — US disclosed
US-20240066136-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI), INC. (CN) 2024-02-29 — — US disclosed
EP-3442518-B1 METHODS OF TREATMENT FOR CHOLESTATIC AND FIBROTIC DISEASES GENFIT (FR) 2024-01-17 — — EP disclosed
CN-116472292-A Modified proteins and protein degrading agents 上海睿跃生物科技有限公司 2023-07-21 — — CN disclosed
CN-116456980-A Application of thiazole compounds in preparation of medicines for treating and preventing cancers 北京大学 2023-07-18 — — CN disclosed
WO-2023058046-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF NITAZOXANIDE AND INTERMEDIATES THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) 2023-04-13 — — WO disclosed
EP-4157888-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS Cullgen (Shanghai), Inc. (CN) 2023-04-05 — — EP disclosed
CN-109152760-B Methods of treating cholestatic and fibrotic diseases 基恩菲特公司 2022-09-23 — — CN disclosed
CN-110198708-B Pharmaceutical compositions for combination therapy 基恩菲特公司 2022-09-20 — — CN disclosed
EP-1420784-A1 COMPOUNDS EFFECTING GLUCOKINASE Astrazeneca AB (SE) 2004-05-26 — — EP disclosed
EP-1420828-A2 LIPOPHILIC DRUG COMPOSITIONS Sung, Michael T. (US) 2004-05-26 — — EP disclosed
US-20030108596-A1 Lipophilic drug compositions SUNG, ROSEMARY 2003-06-12 — — US disclosed
WO-2003018064-A2 LIPOPHILIC DRUG COMPOSITIONS SUNG MICHAEL T (US) 2003-03-06 — — WO disclosed
WO-2003015774-A1 COMPOUNDS EFFECTING GLUCOKINASE ASTRAZENECA AB (SE) 2003-02-27 — — WO disclosed
CN-1325389-A 2-aminothiazole derivatives, process for preparing the same and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2001-12-05 — — CN disclosed
US-5935591-A Method for treatment of equine protozoal myeloencephalitis with thiazolides ROMARK LABORATORIES, L.C. (US) 1999-08-10 — — US disclosed
US-5935591-A Method for treatment of equine protozoal myeloencephalitis with thiazolides ROMARK LABORATORIES, L.C. (US) 1999-08-10 — — US disclosed
US-4315018-A Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives ROMARK LABORATORIES, L.C. 1982-02-09 — — US disclosed
US-4315018-A Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives ROMARK LABORATORIES, L.C. 1982-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240417381-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF NITAZOXANIDE AND INTERMEDIATES THEREOF NIT2, NUDT1, QDPR NPC1 2751/4885RAB9A 2152/4885MEN1 1212/4885
US-20240066136-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS DDB1, DCLRE1A, MDM2 NPC1 3949/4885RAB9A 3280/4885MEN1 3254/4885
US-20030108596-A1 Lipophilic drug compositions LIPA, LIPC, PNLIP NPC1 65/4885RAB9A 2575/4885MEN1 3372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.